
    
      A Phase 2, randomized, blinded, 5-period cross-over, placebo and active controlled,
      multicenter, dose-finding study comparing single doses of formoterol 2.25 µg, 4.5 µg, and 9
      µg delivered via Symbicort pMDI and Foradil® 12 µg evaluating the relative bronchodilating
      effects and safety in children.
    
  